Armin Ghobadi, MD, on Assessing CAR-T Cell Combination Therapies

“CAR T is just the start of a big wave. I use the analogy of penicillin when it was invented. It’s a big step but we have ways to go. The only difference here is that we have really advanced technology and tools that we can use to go forward significantly faster. And hopefully in the next few years, we're going to see more and more of those combinations that enhance efficacy and decrease toxicities and cure more patients.”

REFERENCE

Ghobadi A, Budde EL, Galal A, et al. A phase 1b dose expansion study evaluating safety, preliminary anti-tumor activity, and accelerated T cell reconstitution with NT-I7 (Efineptakin Alfa), a long-acting human IL-7, administered following tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, New Orleans, Louisiana.